Lockbaum G, Rusere L, Henes M, Kosovrasti K, Rao D, Spielvogel E
Eur J Med Chem. 2023; 257:115501.
PMID: 37244161
PMC: 10332405.
DOI: 10.1016/j.ejmech.2023.115501.
Spielvogel E, Lee S, Zhou S, Lockbaum G, Henes M, Sondgeroth A
Elife. 2023; 12.
PMID: 36920025
PMC: 10065791.
DOI: 10.7554/eLife.80328.
Ma L, Wen J, Dong B, Zhou J, Hu S, Wang J
Int J Mol Sci. 2022; 23(22).
PMID: 36430656
PMC: 9697080.
DOI: 10.3390/ijms232214178.
Wang H, Mulgaonkar N, Perez L, Fernando S
ACS Omega. 2022; 7(15):12707-12715.
PMID: 35474832
PMC: 9025992.
DOI: 10.1021/acsomega.1c07144.
Lockbaum G, Henes M, Talledge N, Rusere L, Kosovrasti K, Nalivaika E
ACS Chem Biol. 2021; 16(3):529-538.
PMID: 33619959
PMC: 8126997.
DOI: 10.1021/acschembio.0c00975.
Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond.
Matthew A, Leidner F, Lockbaum G, Henes M, Zephyr J, Hou S
Chem Rev. 2021; 121(6):3238-3270.
PMID: 33410674
PMC: 8126998.
DOI: 10.1021/acs.chemrev.0c00648.
The Chiron Approach to (3,3,6)-Hexahydrofuro[2,3-]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir.
Ghosh A, Markad S, Robinson W
J Org Chem. 2020; 86(1):1216-1222.
PMID: 33267583
PMC: 7894212.
DOI: 10.1021/acs.joc.0c02396.
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
Rusere L, Lockbaum G, Henes M, Lee S, Spielvogel E, Rao D
J Med Chem. 2020; 63(15):8296-8313.
PMID: 32672965
PMC: 7971191.
DOI: 10.1021/acs.jmedchem.0c00529.
HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
Rusere L, Lockbaum G, Lee S, Henes M, Kosovrasti K, Spielvogel E
J Med Chem. 2019; 62(17):8062-8079.
PMID: 31386368
PMC: 6941148.
DOI: 10.1021/acs.jmedchem.9b00838.
Synthesis of Bioactive Natural Products by Asymmetric - and -Aldol Reactions.
Ghosh A, Dawson Z
Synthesis (Stuttg). 2018; 2009(17):2992-3002.
PMID: 30443084
PMC: 6233898.
DOI: 10.1055/s-0029-1216941.
A Stereoselective Anti-Aldol Route to (3,3a,6a)-Hexahydrofuro[2,3-] furan-3-ol: A Key Ligand for a New Generation of HIV Protease Inhibitors.
Ghosh A, Li J, Perali R
Synthesis (Stuttg). 2018; 2006(18):3015-3018.
PMID: 30443083
PMC: 6233888.
DOI: 10.1055/s-2006-942547.
Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS.
Ghosh A, Osswald H, Prato G
J Med Chem. 2016; 59(11):5172-208.
PMID: 26799988
PMC: 5598487.
DOI: 10.1021/acs.jmedchem.5b01697.
Pentacycloundecane lactam vs lactone norstatine type protease HIV inhibitors: binding energy calculations and DFT study.
Honarparvar B, Pawar S, Alves C, Lameira J, Maguire G, Silva J
J Biomed Sci. 2015; 22:15.
PMID: 25889635
PMC: 4387594.
DOI: 10.1186/s12929-015-0115-5.
Organic carbamates in drug design and medicinal chemistry.
Ghosh A, Brindisi M
J Med Chem. 2015; 58(7):2895-940.
PMID: 25565044
PMC: 4393377.
DOI: 10.1021/jm501371s.
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors.
Hohlfeld K, Tomassi C, Wegner J, Kesteleyn B, Linclau B
ACS Med Chem Lett. 2014; 2(6):461-5.
PMID: 24900331
PMC: 4018169.
DOI: 10.1021/ml2000356.
The role of select subtype polymorphisms on HIV-1 protease conformational sampling and dynamics.
Huang X, Britto M, Kear-Scott J, Boone C, Rocca J, Simmerling C
J Biol Chem. 2014; 289(24):17203-14.
PMID: 24742668
PMC: 4059161.
DOI: 10.1074/jbc.M114.571836.
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.
Nalam M, Ali A, Reddy G, Cao H, Anjum S, Altman M
Chem Biol. 2013; 20(9):1116-24.
PMID: 24012370
PMC: 3934494.
DOI: 10.1016/j.chembiol.2013.07.014.
Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.
Parai M, Huggins D, Cao H, Nalam M, Ali A, Schiffer C
J Med Chem. 2012; 55(14):6328-41.
PMID: 22708897
PMC: 3409094.
DOI: 10.1021/jm300238h.
Modeling Protein-Ligand Binding by Mining Minima.
Chen W, Gilson M, Webb S, Potter M
J Chem Theory Comput. 2012; 6(11):3540-3557.
PMID: 22639555
PMC: 3359898.
DOI: 10.1021/ct100245n.
Design of substituted bis-Tetrahydrofuran (bis-THF)-derived Potent HIV-1 Protease Inhibitors, Protein-ligand X-ray Structure, and Convenient Syntheses of bis-THF and Substituted bis-THF Ligands.
Ghosh A, Martyr C, Steffey M, Wang Y, Agniswamy J, Amano M
ACS Med Chem Lett. 2012; 2(4):298-302.
PMID: 22509432
PMC: 3325757.
DOI: 10.1021/ml100289m.
